BTIG analyst Julian Harrison reiterated a Buy rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target of ...

Cambridge, Massachusetts Thursday, October 17, 2024, 17:00 Hrs [IST] ...

The primary objective is to evaluate the safety of CLN-978 for the treatment of active moderate to severe SLE, with secondary ...

Cullinan Therapeutics said the U.S. Food and Drug Administration approved its investigation new drug application for CLN-978, a potential treatment for lupus. The biopharmaceutical company said the ...

Inaugural Program Will Recognize Marketing Campaigns, Event Strategies and Brand Awareness Initiatives ...

The long-term risk of distant recurrence for women with early breast cancer has declined significantly, a decades-long ...

Cullinan Therapeutics Files for 14.42M Share Offering by Selling Stockholders Cullinan Therapeutics (CGEM) has filed for up to 14,421,070 share offering by selling stockholders.

In fact, the refreshed Cullinan – which is getting larger (23-inch) wheels, a fresh look at the front, new interior materials, and additional personalization options along with an upgraded ...

Marburg vaccines are set to arrive in Rwanda in the coming days to help protect healthcare workers fighting an outbreak of ...

But before that happens, Rolls-Royce is trying to redirect our attention from the refreshed Cullinan Series II until it can ramp up sufficient production with news of its latest Private Office ...

Rolls-Royce’s updated Cullinan Series II has arrived in Australia for a special preview designed to woo Australia’s richest drivers into dropping a seven-figure sum on their ultimate ride.

Followed categories will be added to My News. Rolls-Royce’s updated Cullinan Series II has arrived in Australia for a special preview designed to woo Australia’s richest drivers into dropping ...